Press Releases

Date Title and Summary Additional Formats
Toggle Summary CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , Nov. 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, November 7th by  Aravive, Inc. (Nasdaq: ARAV), please note that in the last sentence of the second paragraph, the year for the IgA Nephropathy study should be 2019, not 2020.
View HTML
Toggle Summary Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
View HTML
Toggle Summary Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research
AVB-500 reduced tumor size and blood vessel density in animal models Study highlights role of GAS6/AXL signaling in promoting tumor angiogenesis through regulation of plasminogen receptor S100A10 Data supports Aravive’s clinical development plan in clear cell renal cell carcinoma (ccRCC) HOUSTON ,
View HTML
Toggle Summary Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
Company additionally reports data on initial 28 evaluable patients in ongoing expansion study as well as expansion cohort dose increase based on drug exposure-response analysis   HOUSTON , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial
View HTML
Toggle Summary Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference
HOUSTON , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
View HTML
Toggle Summary Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
Early Efficacy Data from Phase 1b/2 Study of AVB500 in Combination with Standard Chemotherapy in Patients with Platinum Resistant Ovarian Cancer to be Presented HOUSTON , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been
View HTML
Toggle Summary Aravive Announces Executive Management Transition Plan
CEO Jay Shepard to step down from his current role after a successor is appointed HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including
View HTML
Toggle Summary Aravive Announces Participation at Wedbush PacGrow Healthcare Conference
HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, today announced that company management will participate at the following upcoming investor
View HTML
Toggle Summary Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
View HTML
Toggle Summary Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollment in Phase 1b Trial of AVB-500 in platinum-resistant ovarian cancer HOUSTON , July 31, 2019 (GLOBE NEWSWIRE) -- Aravive Inc.
View HTML